Author
Neerav Goyal, MD, MPH, FACS Associate Professor of Otolaryngology-Head and Neck Surgery, Neurosurgery, and Public Health Sciences, Pennsylvania State University College of Medicine; Chief, Division of Head and Neck Oncology and Surgery, Fellowship Director, Head and Neck Surgical Oncology Fellowship, Associate Director, Skull Base and Pituitary Center, Department of Otolaryngology-Head and Neck Surgery, Penn State Milton S Hershey Medical Center, Penn State Cancer Institute
Neerav Goyal, MD, MPH, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society
Disclosure: Received research grant from: Medrobotics, Inc; Synthes, Inc.
Coauthor(s)
Aaron Baker, MS Pennsylvania State University College of Medicine
Aaron Baker, MS is a member of the following medical societies: American Medical Association
Disclosure: Nothing to disclose.
Johnathan D McGinn, MD, FACS Professor, Vice Chair, Residency Program Director, Department of Otolaryngology-Head and Neck Surgery, Department of Surgery, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine
Johnathan D McGinn, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Rhinologic Society, Pennsylvania Medical Society, Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Nothing to disclose.
Chief Editor
Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;Cliexa, eMedevents, Neosoma, MI10<br/>Received income in an amount equal to or greater than $250 from: , Cliexa;;Neosoma<br/> Received stock from RxRevu; Received ownership interest from Cerescan for consulting; for: Neosoma, eMedevents, MI10.
